Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study

Arihiro Shoji; Todo Kenichi; Koga Masatoshi; Furui Eisuke; Kinoshita Naoto; Kimura Kazumi; Yamagami Hiroshi; Terasaki Tadashi; Yoshimura Sohei; Shiokawa Yoshiaki; Kamiyama Kenji; Takizawa Shunya; Okuda Satoshi; Okada Yasushi; Nagakane Yoshinari; Kameda Tomoaki; Hasegawa Yasuhiro; Shibuya Satoshi; Ito Yasuhiro; Nakashima Takahiro; Takamatsu Kazuhiro; Nishiyama Kazutoshi; Matsuki Takayuki; Homma Kazunari; Takasugi Junji; Tokunaga Keisuke; Sato Shoichiro; Kario Kazuomi; Kitazono Takanari; Toyoda Kazunori

首页> 外文期刊>International journal of stroke: official journal of the International Stroke Society >Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study

【24h】

Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study

机译：心房颤动卒中后抗凝治疗的三个月风险-获益概况：SAMURAI-非瓣膜性心房颤动（NVAF）研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aims: This study was performed to determine the short-term risk-benefit profiles of patients treated with oral anticoagulation for acute ischemic stroke or transient ischemic attack using a multicenter, prospective registry.

机译：目的：本研究旨在通过多中心，前瞻性研究确定口服抗凝治疗急性缺血性中风或短暂性脑缺血发作的患者的短期风险-获益概况。

著录项

来源
《International journal of stroke: official journal of the International Stroke Society》 |2016年第5期|共10页
作者
Arihiro Shoji; Todo Kenichi; Koga Masatoshi; Furui Eisuke; Kinoshita Naoto; Kimura Kazumi; Yamagami Hiroshi; Terasaki Tadashi; Yoshimura Sohei; Shiokawa Yoshiaki; Kamiyama Kenji; Takizawa Shunya; Okuda Satoshi; Okada Yasushi; Nagakane Yoshinari; Kameda Tomoaki; Hasegawa Yasuhiro; Shibuya Satoshi; Ito Yasuhiro; Nakashima Takahiro; Takamatsu Kazuhiro; Nishiyama Kazutoshi; Matsuki Takayuki; Homma Kazunari; Takasugi Junji; Tokunaga Keisuke; Sato Shoichiro; Kario Kazuomi; Kitazono Takanari; Toyoda Kazunori;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词
Acute stroke care; anticoagulant; atrial fibrillation; cardioembolism; intracranial hemorrhage; stroke outcome; warfarin;

机译：急性中风护理;抗凝剂;心房纤颤;心脏栓塞;颅内出血;中风预后;华法林;

相似文献

外文文献
中文文献
专利

1. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study [J] . Arihiro Shoji, Todo Kenichi, Koga Masatoshi, International journal of stroke: official journal of the International Stroke Society . 2016,第5期

机译：心房颤动卒中后抗凝治疗的三个月风险-获益概况：SAMURAI-非瓣膜性心房颤动（NVAF）研究
2. Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Apostolakis Stavros, Lane Deirdre A., Banerjee Amitava Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：Acostolakis等人关于文章的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R（2）牧草（2）指数在火箭AF中的指数（Rivaroxaban曾经每日，口服，与维生素K拮抗剂相比，直接因子XA抑制预防心房颤动中的中风和栓塞试验）和阿里亚（心房颤动的抗凝和危险因素）研究队列“
3. Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation　― SAMURAI-NVAF Study ― [J] . Sohei Yoshimura, Masatoshi Koga, Shoichiro Sato, Circulation journal . 2018,第7期

机译：非瓣膜性心房颤动急性缺血性卒中的抗凝治疗两年结果― SAMURAI-NVAF研究―
4. Incidence of Atrial Fibrillation After Percutaneous Closure of Patent Foramen Ovale and Small Atrial Septal Defects in Patients Presenting with Cryptogenic Stroke: A Case-Control Study [C] . R.F. Bonvini, R. Sztajzel, M. Righini, World Congress on Heart Disease . 2007

机译：用密码脑卒中患者经皮型卵形卵形卵形卵巢经皮和小间隔缺陷后心房颤动的发生率：案例对照研究
5. The influence of socioeconomic status on selection of anticoagulation for atrial fibrillation: A population based study. [D] . Sholzberg, Michelle. 2016

机译：社会经济状况对房颤抗凝药物选择的影响：一项基于人群的研究。
6. Anticoagulation for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Risk-Benefit Ratio Remains Highly Favorable [O] . Alberto Maud, Kamakshi Lakshminarayan, Adnan I. Qureshi 2010

机译：老年房颤患者抗凝预防卒中的风险-获益率仍然很高
7. Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts” [O] . Jonathan P. Piccini, Susanna R. Stevens, YuChiao Chang, 2013

机译：回应关于物品的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R 2 Chads 2指数在火箭AF中（rivaroxaban曾经每日，口服，直接因子XA抑制相比维生素K对患者预防心房颤动的卒中和栓塞试验的拮抗剂）和Atria（心房颤动的抗凝和危险因素）研究队列“

Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study

摘要

著录项

相似文献

相关主题

期刊订阅